Overview

Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)

Status:
Not yet recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

01.21 SiroSkin is a phase 3, double-blind, multi-centre, parallel-arm, randomised, placebo-controlled trial to evaluate the use of topical 1% sirolimus in the chemoprevention of skin cancer, versus placebo, applied every night for 6 months in solid organ transplant recipients.

Phase:

Phase 3

Details

Lead Sponsor:

Melanoma and Skin Cancer Trials Limited

Collaborators:

Monash University
The University of Queensland

Treatments:

Sirolimus